{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:14:04Z","timestamp":1783646044054,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51131-8","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:05:01Z","timestamp":1778515501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triple-tracer PET (18F-FDG, 68Ga-DOTANOC, 68Ga-FAPI) maps inter- and intra-lesional heterogeneity in metastatic high-grade neuroendocrine neoplasms"],"prefix":"10.1038","volume":"16","author":[{"given":"Prathap Jayachandra","family":"Hosahalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Somashekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. N.","family":"Bhoomika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. R.","family":"Abhijit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwanath","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth Ramachandra","family":"Guthlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajkumar","family":"Krishnappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mita Kumarswamy","family":"Kallur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak","family":"Wadhwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"Ashwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Rohit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Vivek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suva","family":"Lakshmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajwal Rajaghatta","family":"Kumaraswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Shameer","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"51131_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100510","volume":"23","author":"BE White","year":"2022","unstructured":"White, B. E. et al. Incidence and survival of neuroendocrine neoplasia in England 1995\u20132018: A retrospective, population-based study. Lancet Reg. Health Eur. 23, 100510 (2022).","journal-title":"Lancet Reg. Health Eur."},{"key":"51131_CR2","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","volume":"31","author":"G Rindi","year":"2018","unstructured":"Rindi, G. et al. A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod. Pathol. 31, 1770\u20131786 (2018).","journal-title":"Mod. Pathol."},{"key":"51131_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi, G. et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr. Pathol. 33, 115\u2013154 (2022).","journal-title":"Endocr. Pathol."},{"key":"51131_CR4","doi-asserted-by":"publisher","first-page":"15782","DOI":"10.1038\/s41598-024-66668-9","volume":"14","author":"F Scalorbi","year":"2024","unstructured":"Scalorbi, F. et al. Cylindrical TGR as early radiological predictor of RLT progression in GEPNETs: A proof of concept. Sci. Rep. 14, 15782 (2024).","journal-title":"Sci. Rep."},{"key":"51131_CR5","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s13193-024-02009-6","volume":"15","author":"YC Rekha","year":"2024","unstructured":"Rekha, Y. C., Sriharsha, B., Konan, B., Ram Kumar, K. R. R. & Vivek, T. G. Gastrointestinal neuroendocrine tumors\u2014Case series from a tertiary care center with review of literature. Indian J. Surg. Oncol. 15, 884\u2013890 (2024).","journal-title":"Indian J. Surg. Oncol."},{"key":"51131_CR6","first-page":"471","volume":"68","author":"M Cives","year":"2018","unstructured":"Cives, M. & Strosberg, J. R. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J. Clin. 68, 471\u2013487 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"51131_CR7","doi-asserted-by":"publisher","first-page":"R261","DOI":"10.1530\/ERC-16-0538","volume":"24","author":"WT Zandee","year":"2017","unstructured":"Zandee, W. T., Kamp, K., van Adrichem, R. C., Feelders, R. A. & de Herder, W. W. Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. Endocr. Relat. Cancer. 24, R261\u2013R274 (2017).","journal-title":"Endocr. Relat. Cancer."},{"key":"51131_CR8","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1007\/s00259-025-07073-w","volume":"52","author":"E Calder\u00f3n","year":"2025","unstructured":"Calder\u00f3n, E. et al. One-day dual-tracer examination in neuroendocrine neoplasms: A real advantage of low activity LAFOV PET imaging. Eur. J. Nucl. Med. Mol. Imaging. 52, 2463\u20132476 (2025).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"51131_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11912-021-01139-2","volume":"23","author":"J Refardt","year":"2021","unstructured":"Refardt, J., Hofland, J., Wild, D. & Christ, E. New directions in imaging neuroendocrine neoplasms. Curr. Oncol. Rep. 23, 143 (2021).","journal-title":"Curr. Oncol. Rep."},{"key":"51131_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13474","volume":"37","author":"M Di Franco","year":"2025","unstructured":"Di Franco, M., Fortunati, E., Zanoni, L., Fanti, S. & Ambrosini, V. The role of combined FDG and SST PET\/CT in neuroendocrine tumors. J. Neuroendocrinol. 37, e13474 (2025).","journal-title":"J. Neuroendocrinol."},{"key":"51131_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.molonc.2015.08.001","volume":"10","author":"MM Koczorowska","year":"2016","unstructured":"Koczorowska, M. M. et al. Fibroblast activation protein-\u03b1, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Mol. Oncol. 10, 40\u201358 (2016).","journal-title":"Mol. Oncol."},{"key":"51131_CR12","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2741\/4682","volume":"23","author":"P Busek","year":"2018","unstructured":"Busek, P., Mateu, R., Zubal, M., Kotackova, L. & Sedo, A. Targeting fibroblast activation protein in cancer - Prospects and caveats. Frontiers in bioscience (Landmark edition) 23, 1933\u20131968 (2018).","journal-title":"Frontiers in bioscience (Landmark edition)"},{"key":"51131_CR13","first-page":"83","volume":"11","author":"M Palihati","year":"2025","unstructured":"Palihati, M., Das, J. P., Yeh, R. & Capaccione, K. Emerging PET imaging agents and targeted radioligand therapy: A review of clinical applications and trials. Tomography (Ann Arbor, Mich.) 11, 83 (2025).","journal-title":"Tomography (Ann Arbor, Mich.)"},{"key":"51131_CR14","doi-asserted-by":"publisher","first-page":"7804","DOI":"10.1007\/s00330-024-10843-z","volume":"34","author":"R Tang","year":"2024","unstructured":"Tang, R., Liu, M., Shu, Q., Chen, X. & Cai, L. Performance of fibroblast activating protein inhibitor PET imaging for pancreatic neoplasms assessment: A systematic review and meta-analysis. Eur. Radiol. 34, 7804\u20137812 (2024).","journal-title":"Eur. Radiol."},{"key":"51131_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1523-1747.2003.12035.x","volume":"120","author":"MA Huber","year":"2003","unstructured":"Huber, M. A. et al. Fibroblast activation protein: Differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J. Invest. Dermatol. 120, 182\u20138 (2003).","journal-title":"J. Invest. Dermatol."},{"key":"51131_CR16","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner, T. et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J. Nucl. Med. 59, 1415\u20131422 (2018).","journal-title":"J. Nucl. Med."},{"key":"51131_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2967\/jnumed.119.233122","volume":"61","author":"T Watabe","year":"2020","unstructured":"Watabe, T. et al. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models. Journal of nuclear medicine\u202f: official publication, Society of Nuclear Medicine 61, 563\u2013569 (2020).","journal-title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine"},{"key":"51131_CR18","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","volume":"48","author":"FL Giesel","year":"2021","unstructured":"Giesel, F. L. et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients. Eur. J. Nucl. Med. Mol. Imaging 48, 4377\u20134385 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"51131_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil, C. et al. 68Ga-FAPI PET\/CT: Tracer uptake in 28 different kinds of cancer. J. Nucl. Med. 60, 801\u2013805 (2019).","journal-title":"J. Nucl. Med."},{"key":"51131_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","volume":"2","author":"Y Mori","year":"2024","unstructured":"Mori, Y. et al. Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET). npj Imaging 2, 48 (2024).","journal-title":"npj Imaging"},{"key":"51131_CR21","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0895-4356(03)00177-X","volume":"56","author":"AS Glas","year":"2003","unstructured":"Glas, A. S., Lijmer, J. G., Prins, M. H., Bonsel, G. J. & Bossuyt, P. M. M. The diagnostic odds ratio: A single indicator of test performance. J. Clin. Epidemiol. 56, 1129\u201335 (2003).","journal-title":"J. Clin. Epidemiol."},{"key":"51131_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/RLU.0000000000004438","volume":"48","author":"W-Y Chang","year":"2023","unstructured":"Chang, W.-Y. et al. Comparison of the detection performance between FAP and FDG PET\/CT in various cancers: A systemic review and meta-analysis. Clin. Nucl. Med. 48, 132\u2013142 (2023).","journal-title":"Clin. Nucl. Med."},{"key":"51131_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00846-y","volume":"11","author":"C Sachpekidis","year":"2021","unstructured":"Sachpekidis, C. et al. The prognostic significance of [18F]FDG PET\/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Res. 11, 100 (2021).","journal-title":"EJNMMI Res."},{"key":"51131_CR24","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3390\/cancers14122925","volume":"14","author":"P Palmisciano","year":"2022","unstructured":"Palmisciano, P. et al. The role of [68Ga]Ga-DOTA-SSTR PET radiotracers in brain tumors: A systematic review of the literature and ongoing clinical trials. Cancers 14, 2925 (2022).","journal-title":"Cancers"},{"key":"51131_CR25","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1097\/RLU.0000000000000816","volume":"40","author":"G Savelli","year":"2015","unstructured":"Savelli, G. & Muni, A. Somatostatin receptors in an anaplastic oligodendroglioma relapse evidenced by 68Ga DOTANOC PET\/CT. Clin. Nucl. Med. 40, e363-5 (2015).","journal-title":"Clin. Nucl. Med."},{"key":"51131_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32090497","volume":"32","author":"A Zaidi","year":"2025","unstructured":"Zaidi, A. et al. Dual PET imaging with [68Ga] Ga\u2011DOTA\u2011TOC and [18F] FDG to localize neuroendocrine tumors of unknown origin. Curr. Oncol. 32, 497 (2025).","journal-title":"Curr. Oncol."},{"key":"51131_CR27","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1097\/RLU.0000000000003490","volume":"46","author":"H K\u00f6mek","year":"2021","unstructured":"K\u00f6mek, H., G\u00fcndo\u011fan, C. & Can, C. 68Ga-FAPI PET\/CT versus 68Ga-DOTATATE PET\/CT in the evaluation of a patient with neuroendocrine tumor. Clin. Nucl. Med. 46, e290\u2013e292 (2021).","journal-title":"Clin. Nucl. Med."},{"key":"51131_CR28","first-page":"2365 LP \u2013 2365","volume":"63","author":"M Yadav","year":"2022","unstructured":"Yadav, M. et al. [68Ga]-DOTA.SA.FAPi PET\/CT in grade 3 neuroendocrine tumors: A paradigm shift in the molecular imaging. J. Nuclear Med. 63, 2365 LP \u2013 2365 (2022).","journal-title":"J. Nuclear Med."},{"key":"51131_CR29","first-page":"1899","volume":"65","author":"K Michalski","year":"2024","unstructured":"Michalski, K. et al. [18F]FDG and [68Ga]Ga-FAPI-04 imaging for outcome prediction in patients with high-grade neuroendocrine neoplasms. J. Nucl. Med. 65, 1899\u20131903 (2024).","journal-title":"J. Nucl. Med."},{"key":"51131_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040521","author":"S Ballal","year":"2023","unstructured":"Ballal, S. et al. Head-to-head comparison between [68Ga]Ga-DOTA.SA.FAPi and [18F]F-FDG PET\/CT imaging in patients with breast cancer. Pharmaceuticals (Basel, Switzerland) https:\/\/doi.org\/10.3390\/ph16040521 (2023).","journal-title":"Pharmaceuticals (Basel, Switzerland)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51131-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51131-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51131-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:35:23Z","timestamp":1783643723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51131-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51131"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51131-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21559"}}